People · Operator

Daniel D. Von Hoff, M.D., F.A.C.P.

Named in public records as an officer, director or promoter · active 2010–2013 · Biotechnology

1
Companies
2
Filings
$22.6M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Cylene Pharmaceuticals, Inc.BiotechnologySeries B$22.6M$34.4M2010
Operator network

Daniel D. Von Hoff, M.D., F.A.C.P. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Fred A. Middleton · 9 companies · 1 sharedFred A. MiddletonS Edward Torres · 8 companies · 1 sharedS Edward TorresReinhard J. Ambros · 3 companies · 1 sharedReinhard J. AmbrosWILLIAM G RICE · 2 companies · 1 sharedWILLIAM G RICEDaniel D. Von Hoff · 1 companies · 1 sharedDaniel D. Von HoffErich G. Platzer · 1 companies · 1 sharedErich G. PlatzerErich G. Platzer, M.D. · 1 companies · 1 sharedErich G. Platzer,…Peter J. Feinstein · 1 companies · 1 sharedPeter J. FeinsteinReinhard J. Ambros, Ph.D. · 1 companies · 1 sharedReinhard J. Ambro…Shaun A. Kirkpatrick · 1 companies · 1 sharedShaun A. Kirkpatr…William G. Rice, Ph.D. · 1 companies · 1 sharedWilliam G. Rice, …Cylene Pharmaceuticals, Inc. · $22.6M raisedCylene Pharmaceutical…Daniel D. Von Hoff, M.D., F.A.C.P.DF
Daniel D. Von Hoff, M.D., F… Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Daniel D. Von Hoff, M.D., F.A.C.P. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Fred A. Middleton19
S Edward Torres18
Reinhard J. Ambros13
WILLIAM G RICE12
Erich G. Platzer, M.D.11
Reinhard J. Ambros, Ph.D.11
Peter J. Feinstein11
William G. Rice, Ph.D.11
Shaun A. Kirkpatrick11
Erich G. Platzer11
Daniel D. Von Hoff11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.